Article Sidebar

pdf
Date Published: 05/05/2024
Abstract Views: 40
Views pdf: 24
DOI: https://doi.org/10.51298/vmj.v538i1.9326
Issue
Vol. 538 No. 1 (2024)
Section
Các bài báo
How to Cite
Nguyễn, H., & Trịnh, H. S. (2024). POST HEPATECTOMY COMPLICATION WITH PREOPERATIVE TRANSARTERIAL EMBOLIZATION OF HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 538(1). https://doi.org/10.51298/vmj.v538i1.9326

POST HEPATECTOMY COMPLICATION WITH PREOPERATIVE TRANSARTERIAL EMBOLIZATION OF HEPATOCELLULAR CARCINOMA

Hoàng Nguyễn, Hồng Sơn Trịnh

Main Article Content

Abstract

Objectives: To describe the clinical, paraclinical and complications of hepatectomy with transarterial chemoembolization (TACE) pre operation for hepatocellular carcinoma (HCC). Methods: A prospective descriptive study on 44 patients HCC with preoperative TACE. Results and discussion: Mean age 48,8±13 . Ratio Female/Male = 4/1. The rate of patients with hepatitis B was 41 patients (89.1%), and hepatitis C was 2 patients (4,3%). Most patients without syndromes. The rate of increased AFP was 29 patients (60,9%). There were 25 patients (54,3%) had TACE once and 21 patients (45,7%) had TACE more than once. The majority of patients had major hepatectomy, up to 28 patients (60.9%), the necrosis tumor rate was less than 100% in 36 patients (78,3%). The rate of complications in our study was 10,9% in 5 patients, of which the main complications were pleural effusion in 4 patients (8,7%), 2 patients with liver failure after surgery. (4,3%) and 1 case of acute renal failure (2,2%). Conclusions: Hepatectomy with TACE preoperation has a low complication rate, the complications are mainly minor complications and preoperative TACE increases the rate of patients undergoing surgery, improve postoperative survival.

Article Details

Keywords

Hepatocellular carcinoma, transarterial chemoembolization (TACE).

References

1. Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: current management. Curr Probl Surg. 2010 Jan;47(1):10–67.
2. Cherqui D, Belghiti J. [Hepatic surgery. What progress? What future?]. Gastroenterol Clin Biol. 2009;33(8–9):896–902.
3. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol. 2013 Jan;42(1):151–60.
4. Kang JY, Choi MS, Kim SJ, Kil JS, Lee JH, Koh KC, et al. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. Korean J Hepatol. 2010 Dec;16(4): 383–8.
5. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001 Feb;5(1):145–59.
6. Lee KT, Lu YW, Wang SN, Chen HY, Chuang SC, Chang WT, et al. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol. 2009 May 1;99(6):343–50.
7. Virani S, Michaelson JS, Hutter MM, Lancaster RT, Warshaw AL, Henderson WG, et al. Morbidity and mortality after liver resection: results of the patient safety in surgery study. J Am Coll Surg. 2007 Jun;204(6):1284–92.
8. Foster JH, Berman MM. Solid liver tumors. Major Probl Clin Surg. 1977;22:1–342.
9. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg. 2007 May;204(5):854–62; discussion 862-864.
10. Zhou Y, Zhang X, Wu L, Ye F, Su X, Shi L, et al. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. BMC Gastroenterol. 2013 Mar 19;13:51.